Omeros Corp. is confronting a regulatory split that has traders watching the chart as closely as the headline. The European Medicines Agency rejected narsoplimab for a second time, and Omeros shares fell below a key technical support level for the first time in nearly three months.

The break matters because it turns a European regulatory setback into a US-listed market event. Narsoplimab remains approved by the US Food and Drug Administration under the brand name Yartemlea, with that approval granted in December 2025. But the second European rejection has introduced a fresh source of uncertainty around how investors may value the drug across different markets.

One drug, two regulatory outcomes

For Omeros, the contrast is unusually stark. The company has an FDA-approved product in the United States, yet narsoplimab has now been rejected twice by the EMA. The European decision does not change the existing US approval status of Yartemlea, but it may complicate the broader commercial narrative surrounding the therapy.

That divergence can matter to a biotechnology stock because regulatory outcomes are not merely administrative milestones. They can influence expectations about a product's geographic reach, potential revenue opportunities and the resources required to pursue additional approvals. In Omeros' case, the US approval provides an established regulatory foothold, while the repeated European setback narrows the immediate story on that side of the Atlantic.

As the reported market reaction shows, traders responded not just to the EMA decision but also to the stock's technical behavior. Omeros fell through support that had held for nearly three months. No specific price level is needed to understand the signal: a previously watched floor has been breached.

Why the support break is now in focus

Technical support is less a magic line than a shared point of reference. When a stock remains above it, traders may interpret that area as evidence that buyers are still willing to defend the price. Once the level gives way, that assumption may weaken.

For Omeros, traders may now monitor whether the breached support level can be reclaimed or whether it begins acting as resistance. Continued trading below it could suggest that downside pressure is persisting after the regulatory news. A move back above the level, by contrast, could indicate that the initial reaction is losing force. Neither outcome is assured, and the assignment does not establish a specific price target or further decline.

The US approval remains the anchor

The most important distinction for investors is that the EMA rejection is not a withdrawal of Yartemlea's FDA approval. Omeros still has a US-approved narsoplimab product, following the December 2025 decision. The market is therefore weighing two facts at once: a meaningful US regulatory achievement and a second European rejection.

That creates a stock story with competing signals. The fundamental picture retains a US approval foundation, while the chart is flashing caution after the loss of key support. For traders, the next question may be whether Omeros can stabilize above a new level or whether the European setback continues to pressure sentiment. For longer-horizon market watchers, the debate may center on how much weight to assign the US approval versus the limits exposed by the European outcome.